Prospective, doubleblind, randomized, placebocontrolled Trial with Abciximab to reduce coronary microembolism during PCI in patient with stable angina pectoris.

Trial Profile

Prospective, doubleblind, randomized, placebocontrolled Trial with Abciximab to reduce coronary microembolism during PCI in patient with stable angina pectoris.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Abciximab (Primary)
  • Indications Embolism
  • Focus Biomarker; Therapeutic Use
  • Acronyms REOPRO-HITS
  • Most Recent Events

    • 09 Feb 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2010-019688-12).
    • 09 Feb 2013 Planned End Date (18 Apr 2011) added as reported by European Clinical Trials Database.
    • 06 Jul 2012 Planned initiation date (12 Dec 2010) added as reported by German Clinical Trials Register record..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top